Table 1.
Patients and tumor characteristics of TFE3-rearranged RCC and TFE3(+) ccRCC and comparison between them.
| TFE3(+) RCC (n = 37) | TFE3-rearranged RCC (n = 13) | TFE3(+) ccRCC (n = 24) | P | |
|---|---|---|---|---|
| Age | 45.00 [28.00, 53.00] | 33.00 [19.00, 45.00] | 48.50 [39.50, 56.25] | 0.011* |
| Sex | 0.541 | |||
| Male | 21 (56.76) | 6 (46.15) | 15 (62.50) | |
| Female | 16 (43.24) | 7 (53.85) | 9 (37.50) | |
| BMI | 21.94 [20.07, 24.91] | 20.08 [18.96, 22.72] | 22.22 [21.65, 27.15] | 0.056 |
| Chief complaint | 0.904 | |||
| Examination | 19 (51.35) | 6 (46.15) | 13 (54.17) | |
| Symptom | 18 (48.65) | 7 (53.85) | 11 (45.83) | |
| Laterality | 0.570 | |||
| Left | 18 (48.65) | 5 (38.46) | 13 (54.17) | |
| Right | 19 (51.35) | 8 (61.54) | 11 (45.83) | |
| Diameter (cm) | 5.90 [4.00, 8.72] | 5.30 [4.00, 8.60] | 5.95 [4.00, 8.72] | 0.906 |
| T | 0.688 | |||
| T1 | 24 (66.67) | 7 (58.33) | 17 (70.83) | |
| T2 | 7 (19.44) | 3 (25.00) | 4 (16.67) | |
| T3 | 4 (11.11) | 2 (16.67) | 2 (8.33) | |
| T4 | 1 (2.78) | 0 (0.00) | 1 (4.17) | |
| N | 1.000 | |||
| N0 | 32 (88.89) | 11 (91.67) | 21 (87.50) | |
| N1 | 4 (11.11) | 1 (8.33) | 3 (12.50) | |
| M | 0.253 | |||
| M0 | 33 (91.67) | 10 (83.33) | 23 (95.83) | |
| M1 | 3 (8.33) | 2 (16.67) | 1 (4.17) | |
| AJCC group | 0.591 | |||
| Stage I | 24 (66.67) | 7 (58.33) | 17 (70.83) | |
| Stage II | 5 (13.89) | 2 (16.67) | 3 (12.50) | |
| Stage III | 4 (11.11) | 1 (8.33) | 3 (12.50) | |
| Stage IV | 3 (8.33) | 2 (16.67) | 1 (4.17) | |
| Surgery | 0.744 | |||
| RN | 20 (54.1) | 8 (61.54) | 12 (50.00) | |
| nonRN | 17 (45.9) | 5 (38.46) | 12 (50.00) | |
| Drug therapy | 0.262 | |||
| Yes | 8 (24.24) | 5 (38.46) | 3 (15.00) | |
| No | 25 (75.76) | 8 (61.54) | 17 (85.00) | |
| NLR | 2.15 [1.72, 3.14] | 1.62 [1.35, 1.93] | 2.74 [2.13, 3.42] | 0.001** |
| Scr | 77.50 [65.25, 89.50] | 68.00 [62.75, 84.25] | 81.50 [71.75, 90.25] | 0.202 |
| FISH detection | <0.001*** | |||
| Positive | 13 (35.14) | 13 (100.00) | 0 (0.00) | |
| Negative | 24 (64.86) | 0 (0.00) | 24 (100.00) | |
| LVI | 0.361 | |||
| Yes | 5 (14.71) | 3 (27.27) | 2 (8.70) | |
| No | 29 (85.29) | 8 (72.73) | 21 (91.30) | |
| IHC_TFE3 | NA | |||
| + | 37 (100.00) | 13 (100.00) | 24 (100.00) | |
| - | 0 (0.00) | 0 (0.00) | 0 (0.00) | |
| Ki67 | 9.00 [5.00, 15.00] | 8.00 [5.00, 15.00] | 10.00 [5.00, 15.00] | 0.973 |
| Recurrence | 0.951 | |||
| Yes | 4 (11.11) | 2 (15.38) | 2 (8.70) | |
| No | 32 (88.89) | 11 (84.62) | 21 (91.30) | |
| Metastasis | 0.841 | |||
| Yes | 9 (25.00) | 4 (30.77) | 5 (21.74) | |
| No | 27 (75.00) | 9 (69.23) | 18 (78.26) | |
| Survival status | 0.315 | |||
| Alive | 33 (89.19) | 13 (100.00) | 20 (83.33) | |
| Dead | 4 (10.81) | 0 (0.00) | 4 (16.67) |
TFE3-rearranged RCC, TFE3-rearranged renal cell carcinoma; TFE3(+) ccRCC, ccRCC with positive TFE3 immunohistochemistry; BMI, body mass index; AJCC, American Joint Committee on Cancer; RN, partial nephrectomy; NLR, neutrophil/lymphocyte ratio; Scr, serum creatinine; LVI, lymphovascular invasion; IHC, immunohistochemistry. *, 0.01 < P < 0.05; **, 0.001 < P < 0.01; ***, P < 0.001.